Prognostic value of metastatic pattern in colorectal cancer: a multicenter retrospective analysis in a real-life cohort

被引:8
|
作者
Rumpold, H. [1 ]
Kirchweger, P. [1 ,2 ]
Niedersuss-Beke, D. [3 ]
Falch, D. [3 ]
Wundsam, H. [4 ]
Metz-Gercek, S. [5 ]
Piringer, G. [2 ,6 ]
Thaler, J. [6 ]
机构
[1] Ordensklinikum Linz, Gastrointestinal Canc Ctr, Seilerstaette 4, A-4010 Linz, Austria
[2] Johannes Kepler Univ Linz, Med Fac, Linz, Austria
[3] Wilhelminenspital Stadt Wien, Dept Internal Med 1, Vienna, Austria
[4] Ordensklinikum Linz, Dept Gen & Visceral Surg, Linz, Austria
[5] Clin Canc Ctr Upper Austria, Linz, Austria
[6] Hosp Wels Grieskirchen, Dept Internal Med 4, Wels, Austria
关键词
Colorectal cancer; real-life; metastasis; prognosis; treatment; PULMONARY METASTASES; RESECTION;
D O I
10.1080/0284186X.2020.1837945
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Metastatic patterns have been linked with prognosis in colorectal cancer. We aim to determine the distribution of metastases, their dynamics during disease and their prognostic impact for specific clinical treatment scenarios (resection of metastasis and/or systemic treatment, best supportive care). Material and methods 978 patients diagnosed with metastatic colorectal adenocarcinoma treated at three oncological centers from 2006 to 2018 were included. Overall survival was assessed depending on tumor load, distribution of metastases and treatment of the patients. Results Most patients had single site metastasis (n = 684; 69.9%): 398 patients had liver (n = 398; 40.7%) and 103 patients had lung only metastasis (10.6%). The number of organs involved in metastases at diagnosis was highly prognostic (HR 0.77; CI 0.65, 0.90), whereas the additional gain of metastases during progression of the disease was not. The majority of patients (62.9-74.2%) with initial lung, liver or both metastases retained their initial metastatic status. In the overall population, lung only metastases were associated with the most favorable outcome (HR 0.64; CI 0.50, 0.81). This was also observed in patients receiving best supportive care (HR 0.45; CI 0.27, 0.75). Resection of lung only metastases resulted in longer median survival (102.2 months). A relevant survival difference in patients treated by systemic therapy alone was not observed. Lung only metastasis was associated with rectal cancer (p < .001) and RAS-mutation (p = .01); both, lung and liver metastasis were associated with time from diagnosis to first metastasis (p < .001). Conclusion The number of organs involved in metastasis at diagnosis but not the total cumulative number of involved organs is of prognostic relevance in colorectal adenocarcinoma. This prognostic relevant initial metastasis distribution remains unchanged in the majority of patients during the disease. However, the prognostic impact of the metastatic pattern is potentially altered by treatment modality.
引用
收藏
页码:180 / 186
页数:7
相关论文
共 50 条
  • [41] Effectiveness, safety and pattern of bevacizumab (BY) use in 1st-line therapy metastatic colorectal cancer (mCRC) in real-life practice: results of the ETNA cohort study
    Fourrier-Reglat, A.
    Smith, D.
    Ravaud, A.
    Rouyer, M.
    Balestra, A.
    Bernard, M. A.
    Moore, N.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2010, 24 : 68 - 68
  • [42] The Prognostic and Predictive Value of Soluble Type IV Collagen in Colorectal Cancer: A Retrospective Multicenter Study
    Rolff, Hans Christian
    Christensen, Ib Jarle
    Vainer, Ben
    Svendsen, Lars Bo
    Eefsen, Rikke Lovendahl
    Wilhelmsen, Michael
    Lund, Ida Katrine
    Hoyer-Hansen, Gunilla
    Nielsen, Hans Jorgen
    Illemann, Martin
    CLINICAL CANCER RESEARCH, 2016, 22 (10) : 2427 - 2434
  • [43] Prognostic value of biomarkers in metastatic colorectal cancer patients
    Kataoka, Kozo
    Kanazawa, Akiyoshi
    Nakajima, Akio
    Yamaguchi, Ayane
    Arimoto, Akira
    JOURNAL OF SURGICAL RESEARCH, 2015, 194 (02) : 343 - 350
  • [44] The prognostic value of lymph node yield in the earliest stage of colorectal cancer: a multicenter cohort study
    Backes, Yara
    Elias, Sjoerd G.
    Bhoelan, Bibie S.
    Groen, John N.
    van Bergeijk, Jeroen
    Seerden, Tom C. J.
    Pullens, Hendrikus J. M.
    Spanier, Bernhard W. M.
    Geesing, Joost M. J.
    Kessels, Koen
    Kerkhof, Marjon
    Siersema, Peter D.
    Cappel, Wouter H. de Vos Tot Nederveen
    van Lelyveld, Niels
    Wolfhagen, Frank H. J.
    ter Borg, Frank
    Offerhaus, G. Johan A.
    Lacle, Miangela M.
    Moons, Leon M. G.
    BMC MEDICINE, 2017, 15
  • [45] The prognostic value of lymph node yield in the earliest stage of colorectal cancer: a multicenter cohort study
    Yara Backes
    Sjoerd G. Elias
    Bibie S. Bhoelan
    John N. Groen
    Jeroen van Bergeijk
    Tom C. J. Seerden
    Hendrikus J. M. Pullens
    Bernhard W. M. Spanier
    Joost M. J. Geesing
    Koen Kessels
    Marjon Kerkhof
    Peter D. Siersema
    Wouter H. de Vos tot Nederveen Cappel
    Niels van Lelyveld
    Frank H. J. Wolfhagen
    Frank ter Borg
    G. Johan A. Offerhaus
    Miangela M. Lacle
    Leon M. G. Moons
    BMC Medicine, 15
  • [46] Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands
    Kwakman, Johannes J. M.
    Vink, G.
    Vestjens, J. H.
    Beerepoot, L. V.
    de Groot, J. W.
    Jansen, R. L.
    Opdam, F. L.
    Boot, H.
    Creemers, G. J.
    van Rooijen, J. M.
    Los, M.
    Vulink, A. J. E.
    Schut, H.
    van Meerten, E.
    Baars, A.
    Hamberg, P.
    Kapiteijn, E.
    Sommeijer, D. W.
    Punt, C. J. A.
    Koopman, M.
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (03) : 482 - 489
  • [47] RAS-mutations in population-based and real-life metastatic colorectal cancer cohorts
    Osterlund, E.
    Ristimaki, A.
    Kytola, S.
    Heerva, E.
    Uutela, A.
    Muhonen, T.
    Halonen, P.
    Kallio, R.
    Soveri, L.
    Sundstrom, J.
    Algars, A.
    Ristamaki, R.
    Sorbye, H.
    Pfeiffer, P.
    Nunes, L.
    Salminen, T.
    Lamminmaki, A.
    Makinen, M.
    Sjoblom, T.
    Isoniemi, H.
    Glimelius, B.
    Osterlund, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S9 - S10
  • [48] Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands
    Johannes J. M. Kwakman
    G. Vink
    J. H. Vestjens
    L. V. Beerepoot
    J. W. de Groot
    R. L. Jansen
    F. L. Opdam
    H. Boot
    G. J. Creemers
    J. M. van Rooijen
    M. Los
    A. J. E. Vulink
    H. Schut
    E. van Meerten
    A. Baars
    P. Hamberg
    E. Kapiteijn
    D. W. Sommeijer
    C. J. A. Punt
    M. Koopman
    International Journal of Clinical Oncology, 2018, 23 : 482 - 489
  • [49] How are elderly patients treated after a diagnosis of metastatic colorectal cancer in real-life practice?
    Gouverneur, A.
    Rouyer, M.
    Grelaud, A.
    Colombani, F.
    Terrebonne, E.
    Smith, D.
    Fourrier-Reglat, A.
    Noize, P.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2015, 29 : 71 - 72
  • [50] Outcomes and predictive factors of regorafenib benefit in patients with metastatic colorectal cancer in a real-life setting
    Martinez Lago, N.
    Carnero Lopez, B.
    De la Camara Gomez, J.
    Vazquez-Rivera, F.
    Fernandez Montes, A.
    de Dios, N.
    Carral Maseda, A.
    Pellon Augusto, M.
    Candamio Folgar, S.
    Reboredo-Lopez, M.
    Salgado Fernandez, M.
    Gallardo Martin, E.
    Covela-Rua, M.
    Grana Suarez, B.
    Carmona Campos, M.
    Brozos Vazquez, E.
    Reboredo Rendo, C.
    Quintero Aldana, G.
    Grande Ventura, C.
    Vidal Insua, Y.
    Mendez Mendez, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S130 - S130